Technical Analysis for RENE - Reneuron Group Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical RENE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Upper Bollinger Band Walk | Strength | 3.38% | |
| Multiple of Ten Bearish | Other | 3.38% | |
| Wide Bands | Range Expansion | 3.38% | |
| Upper Bollinger Band Touch | Strength | 3.38% | |
| Pocket Pivot | Bullish Swing Setup | -2.48% | |
| Upper Bollinger Band Walk | Strength | -2.48% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. | |
Free Daily (Stock) Chart Reading
Reneuron Group Plc Description
ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Research Biotechnology Medicine Clinic Life Sciences Earl Cancer Branches Of Biology Therapy Clinical Trial Biology Emerging Technologies Therapies Cell Therapy Nanomedicine Stem Cells Stroke Cell Biology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 173.5 |
| 52 Week Low | 70.0 |
| Average Volume | 193,908 |
| 200-Day Moving Average | 105.35 |
| 50-Day Moving Average | 115.08 |
| 20-Day Moving Average | 123.03 |
| 10-Day Moving Average | 129.60 |
| Average True Range | 8.51 |
| ADX | 30.72 |
| +DI | 26.68 |
| -DI | 12.27 |
| Chandelier Exit (Long, 3 ATRs ) | 121.88 |
| Chandelier Exit (Short, 3 ATRs ) | 127.52 |
| Upper Bollinger Band | 142.89 |
| Lower Bollinger Band | 103.16 |
| Percent B (%b) | 0.86 |
| BandWidth | 32.30 |
| MACD Line | 7.06 |
| MACD Signal Line | 5.14 |
| MACD Histogram | 1.9184 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 145.00 | ||||
| Resistance 3 (R3) | 145.00 | 142.50 | 143.75 | ||
| Resistance 2 (R2) | 142.50 | 140.59 | 142.50 | 143.33 | |
| Resistance 1 (R1) | 140.00 | 139.41 | 138.75 | 140.00 | 142.92 |
| Pivot Point | 137.50 | 137.50 | 136.88 | 137.50 | 137.50 |
| Support 1 (S1) | 135.00 | 135.59 | 133.75 | 135.00 | 132.08 |
| Support 2 (S2) | 132.50 | 134.41 | 132.50 | 131.67 | |
| Support 3 (S3) | 130.00 | 132.50 | 131.25 | ||
| Support 4 (S4) | 130.00 |
